Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R139

—

08f97737-143b-5e6f-80b1-6be380c09138

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
overall_survival_months
59
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.500
  • IL6_JAK_STAT3_SIGNALING+0.500
  • INTERFERON_GAMMA_RESPONSE+0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • INTERFERON_ALPHA_RESPONSE+0.460
  • INFLAMMATORY_RESPONSE+0.440
  • ANGIOGENESIS+0.430
  • WNT_BETA_CATENIN_SIGNALING+0.360
  • COMPLEMENT+0.340
  • HEDGEHOG_SIGNALING+0.340

Top 10 suppressed

  • MYC_TARGETS_V1-0.590
  • E2F_TARGETS-0.540
  • G2M_CHECKPOINT-0.480
  • MYC_TARGETS_V2-0.480
  • MTORC1_SIGNALING-0.380
  • OXIDATIVE_PHOSPHORYLATION-0.380
  • PROTEIN_SECRETION-0.380
  • ANDROGEN_RESPONSE-0.350
  • SPERMATOGENESIS-0.340
  • UNFOLDED_PROTEIN_RESPONSE-0.300

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-0379
medullo-epn-umap@date-based
MedMedulloblastoma0.918
2R83
bladder-landscape@3
——0.914
3TCGA-A2-A0CO-01A-13R-A22K-07
breast-umap@18
—A0.904
4R194
bladder-landscape@3
——0.903
5TCGA-D8-A73U-01A-11R-A33J-07
breast-umap@18
—D0.902
6SRR13311153
bladder-landscape@3
——0.901
7SRR8613803
breast-umap@18
—D0.900
8TCGA-C8-A8HR-01A-11R-A36F-07
breast-umap@18
—A0.898
9SRR23303731
bladder-landscape@3
——0.897
1020120155.TNBC
breast-umap@18
—D0.896

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.500Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.480Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.460Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.440Idelalisib— uncovered
ANGIOGENESIS0.430Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.360Inavolisib— uncovered
COMPLEMENT0.340Inavolisib— uncovered
HEDGEHOG_SIGNALING0.340Inavolisib— uncovered
IL2_STAT5_SIGNALING0.330Idelalisib— uncovered
NOTCH_SIGNALING0.310Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.310Inavolisib— uncovered
COAGULATION0.300Binimetinib— uncovered
MYOGENESIS0.290Inavolisib— uncovered
P53_PATHWAY0.260Idelalisib— uncovered
APICAL_JUNCTION0.240Inavolisib— uncovered
APOPTOSIS0.220Idelalisib— uncovered
KRAS_SIGNALING_UP0.220Inavolisib— uncovered
UV_RESPONSE_DN0.170Inavolisib— uncovered